Insmed Incorporated clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.

1. Notable

   PALM-ILD · Treprostinil Palmitil Inhalation Powder (TPIP)…PALM-ILD · Treprostinil Palmitil Inhalation Powder (TPIP) · Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

   Primary endpoint(s) modified

   Also in this update: Trial sites expanded: 145 → 185 locations

   Insmed Incorporated·Phase 3· NCT07179380· Registry history of NCT07179380 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

2. Notable

   INS1033 in Healthy Participants

   Recruitment opened

   Insmed Incorporated·Phase 1· NCT07765706· Registry history of NCT07765706 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.